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Novelty and Impact  
This study shows that a weighted genomic risk score including 116 CRC susceptibility SNPs is the score 




inclusion of additional SNPs above the genome-wide significance threshold showed no further improvement 
on prediction performance. Modelling the levels of PRS with age and sex in the general UK population 
shows that employing genetic risk profiling can achieve a moderate degree of risk discrimination that could 





Increasing numbers of common genetic variants associated with colorectal cancer (CRC) have been 
identified. This study aimed to determine whether risk prediction based on common genetic variants 
might enable   stratification for CRC risk. Meta-analysis of eleven genome-wide association studies 
(GWAS) comprising 16,871 cases and 26,328 controls was performed to capture CRC susceptibility 
variants. Genetic prediction models with several candidate polygenic risk scores (PRSs) were generated 
from Scottish CRC case–control studies (6478 cases and 11,043 controls), and the score with the best 
performance was then tested in UK Biobank (4800 cases and 20,287 controls). A weighted PRS of 116 
CRC SNPs (wPRS116) was found with the best predictive performance, reporting a c-statistics of 0.60 
and an odds ratio (OR) of 1.46 (95%CI: 1.41-1.50, per SD increase) in Scottish dataset. The predictive 
performance of this wPRS116 was consistently validated in UK Biobank dataset with c-statistics of 0.61 
and an OR of 1.49 (95%CI: 1.44-1.54, per SD increase). Modelling the levels of PRS with age and sex 
in the general UK population shows that employing genetic risk profiling can achieve a moderate degree 







Colorectal cancer (CRC) is one of the most common cancers, with 1.8 million new cases and almost 
0.8 million deaths globally in 2018.1 Substantial evidence showed that screening can reduce CRC 
mortality by allowing early detection and removal of precancerous lesions. Policy makers and clinicians 
rely on risk classification to determine which individuals to screen. To date, these classification schemes 
are predominantly based on age and/or a simple classification of family history. Stratifying the average 
risk population into risk categories offers the potential of tailoring surveillance intensity.  
Comprehensive information on genetic susceptibility could contribute importantly to CRC risk 
stratification, given that the heritability of CRC has been estimated to be around 16%-35%2 and the 
sibling recurrence risk ratio is about 2.0.3 We previously assessed the utility of CRC genetic risk 
profiling with a panel of 10 common genetic variants associated with CRC susceptibility.4 Although 
discrimination ability was low (c-statistic of 0.56), we showed that genotype data provides additional 
information to that from family history alone.4 Others have also showed that personalised screening 
using polygenic risk scores (PRSs) have the potential to identify high-risk subgroups most likely to 
benefit from targeted CRC prevention strategies.5 Incorporating more complete genetic information is 
expected to improve risk stratification and the combined effect of multiple risk loci has the potential to 
achieve a degree of risk discrimination that is useful for CRC risk stratification.  
In this study, we aimed to derive, optimize and test polygenic risk scores (PRSs) for prediction of CRC 
and to apply the PRSs with the best predictive performance in population settings for risk stratification. 
We developed models by incorporating genetic information of CRC and several markers that comprise 
potential CRC risk factors or complex traits co-occurring with CRC. To gauge the broader future 
potential of genetic risk modelling, we assessed the utility of genetic risk scores in categorizing risk 
subgroups within the general population by projecting the risk models to the UK population.  
MATERIALS AND METHODS 
Studies   
We made use of 11 previously published GWASs (i.e., CCRR1,6 CCFR2,7 COIN,8 CORSA,9 Croatia,10 
DACHS,11 FIN,12 NSCCG-OncoArray,13 SCOT,14 UK1,15 and VQ58 16) to generate a list of genetic 
variants associated with CRC risk. A series of Scottish CRC case–control studies were used to test the 
predictive performance of polygenic risk scores (PRSs). The developed PRSs were further evaluated in 
an independent test dataset from UK Biobank. Schematic representation of the study design is shown 
in Supporting Information Fig. S1. Standard quality control (QC) measures were applied to each of the 
datasets. After QC process, a total of 16,871 cases and 26,328 controls were finally included for the 




included for the development of PRSs, and 4,800 cases and 20,287 controls from UK Biobank were 
included to validate the predictive performance of the PRSs developed. Details are described in 
Supporting Information Methods and Table S1. 
Polygenic risk scores 
Genome-wide polygenic score: We performed a meta-GWAS of 11 studies to obtain a list of genome-
wide significant SNPs (p<5×10-8) and their per-allele odds ratios (ORs) and standard errors for CRC 
risk. The meta-analysis SNPs were pruned to only those with an r2 < 0.1 and a distance greater than 500 
kb. For completeness, we also included the genetic risk variants reported in early published CRC 
GWASs (Table S2). A weighted genome-wide PRS (wPRS) was computed using both previously known 
susceptibility variants and independent variants identified by the meta-GWAS. 
Regional genetic scores: We additionally constructed regional genetic scores by including SNPs 
associated with CRC and its risk factors (i.e., vitamin D [VD], C-reactive protein [CRP], body mass 
index [BMI], waist hip rate [WHR], and inflammatory bowel disease [IBD]) by using the 
GENOSCORES library (https://pm2.phs.ed.ac.uk/genoscores/). This is similar to the approach used for 
LDpred,17 in which the correction for linkage disequilibrium (LD) between SNPs was based on pre-
multiplying the vector of weights by the generalized inverse of the correlation matrix estimated from 
1000G reference panel of European ancestry.   
Model development and evaluation 
We constructed prediction models in the Scottish dataset by incorporating genetic CRC risk in forms of 
either PRSs or regional genetic scores with adjustment for the first 10 genetic principal components 
(PCs). A sequence of logistic models was fitted for: (i) a weighted PRS of identified CRC GWAS SNPs; 
(ii) regional genetic scores for CRC; and (iii) regional genetic scores for CRC and other relevant traits. 
A series of stepwise backward logistic regressions was conducted on regional genetic scores to obtain 
an optimized set of scores determined by the Akaike information criterion. The discriminatory accuracy 
of the models was evaluated by the area under the receiver-operating characteristic curve (ROC, known 
as c-statistic) with 10-fold cross-validation. These models were further assessed by the stratification of 
anatomic tumor sites (i.e., proximal colon, distal colon and rectum). The PRS model with the best 
performance was then evaluated in UK Biobank. Odds ratios (OR) were then derived for per SD 
increase in PRS for overall, and site-specific, CRC risk. To simplify the interpretation of PRS, we 
categorized it into percentiles based on its distribution in controls.  
Combined effect of PRS and family history 




additionally calculated the expected information for discrimination (expected weight of evidence, 
denoted as Λ).18 Briefly, the expected information for discrimination is the expected log-likelihood ratio 
in favor of correct assignment as case or control, taken as the average of the values in cases and controls. 
One advantage of using Λ is that the contributions of independent variables to predictive performance 
are additive on the scale of Λ. For a logistic regression model, the sampling distribution of Λ is 
asymptotically Gaussian. In this situation, the c-statistic can be viewed as a mapping of Λ, which takes 
values from 0 to infinity to the interval from 0.5 to 1.18 The rationale and theoretical explanations are 
presented in Supplementary Methods. Family history of colorectal cancer (CRC) was considered as a 
categorical variable, dependent on the presence or absence of at least one first-degree relative affected 
by CRC at any age at the time of recruitment. 
Estimation of absolute risk for developing CRC 
The absolute risk of CRC for individuals in each risk category was calculated after accounting for 
competing risks of dying from causes other than CRC by using the formula described previously.19 
Specifically, we obtained sex- and age-dependent UK CRC incidence and mortality rates for 2016 mid-
year from the Office for National Statistics (http://www.ons.gov.uk/). The mortality rates for non-CRC 
causes were estimated by subtracting the age- and sex-specific CRC mortality rates from the overall 





The meta-analysis of 11 GWASs resulted in the identification of 1,593 genetic variants associated with 
CRC at p<5×10-8. After adding SNPs reported in other GWAS and excluding SNPs in LD, a list of 116 
SNPs (Table S2) were retained for the creation of a weighted polygenic risk score (wPRS116). We 
additionally created 35 regional genetic scores that included 1,593 SNPs with p<5×10-8 (Table 1). We 
also used more liberal p-value thresholds and created 40 genetic scores comprising of 1,837 SNPs at 
p<10-7 and 41 genetic scores comprising of 2,712 SNPs at p<10-6. The genes harbored in these genomic 
regions were annotated and are presented in Table S3. We additionally created 17 regional scores for 
CRP, 5 for VD, 85 for IBD, 69 for BMI and 48 for WHR with p-value threshold setting as 5×10-8. More 
liberal p-value thresholds (p<10-7 and p<10-6) were also applied for these traits, and the number of 
regional genetic scores created and SNPs included are present Table S4. 
We set out to optimize these derived scores by examining their discriminative ability in the Scottish 
dataset (Table S5). More specifically, the combined effect of 116 CRC SNPs in the form of wPRS116 




increase of wPRS116) and showed moderate discriminative ability (c-statistic=0.60) (Table 1). When 
stratifying CRC status by tumor sites, the predictive ability of wPRS116 had less accuracy than that for 
overall CRC risk (Table 1). With inclusion of multiple regional scores, the best model of regional 
genetic risk scores (including 31 CRC scores, 7 CRP scores, 2 VD scores, 25 IBD scores, 18 BMI scores 
and 7 WHR scores) yielded a c-statistics of 0.60 (Table S4). When comparing to the wPRS116, the 
regional scores showed no further improvement on overall CRC prediction (the p-value of likelihood-
ratio test for assessing predictive accuracy between the models of wPRS116 and genetic risk scores was 
close to 1).  
We next tested the predictive performance of wPRS116 in the UK Biobank dataset. Similarly, the 
wPRS116 showed moderate discrimination ability with a c-statistic of 0.610 and an OR of 1.49 (95% CI: 
1.44 to 1.54, p=6.67×10-128, per SD increase) (Table 2). For individuals in the lowest 1% of wPRS116, 
the OR compared with the middle quintile (40%-60%) was 0.32 (95%CI: 0.19 to 0.54, p=8.51×10-6); 
by contrast, for individuals in the highest 1% of the PRS distribution, the corresponding estimated OR 
was 3.25 (95%CI: 2.50 to 4.22, p=1.52×10-17) (Fig.1, Table S6). When considering CRC risk separately 
for proximal colon, distal colon and rectum, it showed no improvement in predictive performance. We 
then explored the modification effect of the wPRS116 by sex, age, or family history, but found no 
evidence of an interaction effect (Table S7, Pinteraction = 0.426 for multiplicative interaction with sex, 
Pinteraction = 0.688 with age, Pinteraction = 0.388 with family history), therefore we did not fit additional 
interaction terms in the model. 
We then assessed the incremental contribution of adding wPRS116 and family history to a baseline model 
of age, sex and the first 10 genetic PCs as predictors in UK Biobank. Baseline model on age, sex and 
the 10 PCs yielded a c-statistic of 0.53, and the corresponding estimate of Λ was 0.01 bits (Table S8). 
When adding family history alone, the c-statistic increased to 0.55 and the corresponding Λ was 0.02 
bits. Adding both family history and wPRS116 yielded c-statistic of 0.610 and an incremental value of 
0.10 bits, which showed significantly improvement over family history alone. We recalibrated the 
posterior probabilities by fitting a logistic regression model with the response variable as outcome and the 
logit of the posterior probability as the predictive variable. It showed that recalibration of the posterior 
probabilities increases the test log-likelihood only by 1 natural log units for baseline + family history and 
showed no increases for the baseline + FH + wPRS116, indicating that both these models were well-calibrated 
(Fig. S2). 
To gauge the potential public health impact of applying such risk prediction model in the general 
population, we estimated the 10-year absolute risk of the general UK population (Fig. S3, Table S9). 
We observed that the estimated absolute CRC risk for individuals at the highest 1% of PRS began to 
increase sharply after 45 years old, and reached a risk of 22.1% in men and 14.4% in women by 75 




average risk at this age as reference threshold (0.48% for man and 0.33% women). Individuals in the 
top 10% of wPRS116 would reach or exceed this level of risk at 45 years old, which is 5 years earlier 
than the average risk population; in contrast, individuals in the bottom 10% of PRS would stay below 
this average risk until 60 years old. If we considered individuals with 10-year absolute risk ≥5% as high 
risk group, with risk strata by wPRS116 in population settings, we will able to identify 10% men and 5% 
women meriting intensive screening at 65 years old.  
DISCUSSION 
In this study we describe a systematic approach to derive, validate and test a number of candidate 
genetic risk scores with incorporating information from hundreds to thousands of common genetic 
variants to predict polygenic susceptibility of CRC. We evaluated the predictive performance of both a 
genomic risk score and a series of regional genetic scores that were built based on the summary statistics 
from multiple GWASs. Our study shows that a weighted genomic risk score including 116 CRC 
susceptibility SNPs is the score with the best performance, while deconstructing genetic risk into 
multiple regional scores or inclusion of additional SNPs above the genome-wide significance threshold 
showed no further improvement on prediction performance. By implementing the PRSs developed, we 
show that the inclusion of genetic factors into a baseline model of age, sex and family history results in 
a significant improvement of CRC risk stratification. It should be noted that family history data in this 
study were collected based on self-reported bowel cancer history of parents and siblings. Therefore any 
potential recall bias on family history may lead to the prediction improvement being less accurate.   
ROC analysis of the genetic model that included wPRS116 showed an improved but still modest 
discriminative performance (c-statistic: 0.60 in Scottish dataset, 0.61 in UK Biobank dataset). To our 
knowledge, the best predictive performance achieved by PRS along with age and family history was 
0.69 and 0.60 for Korean men and women,20 but the SNPs were chosen from the same dataset used to 
generate the model, and therefore the reported c-statistics are likely inflated. Other genetic models 
showed consistently low to modest discriminatory abilities.21 Hsu et al developed sex-specific models 
by using family history and 27 common genetic variants with adjustment of endoscopy history and 
obtained a discrimination ability of 0.59 for men and 0.56 for women.22 Similarly, Smith et al reported 
a c-statistic of 0.57 for genetic risk model combing 41 CRC susceptibility SNPs.23 The most recent 
genetic model for CRC was developed by Jeon et al including 63 CRC susceptibility SNPs and achieved 
a slightly improved predictive accuracy with a c-statistic of 0.59.24 This modest level of test 
performance is consistent across studies, suggesting that risk assessment algorithms based on 
independent SNPs reaching genome-wide significance level have similar performance characteristics 
in European populations. However, it should be kept in mind that our results pertain to the UK 





With the expectation of improving the predictive power of common genetic variants, we additionally 
derived a set of SNPs associated with CRC risk with liberal p-value thresholds to allow the contribution 
of signals from additional susceptibility SNPs that have not been discovered or validated in previous 
GWAS efforts. Any correlation between SNPs was addressed by creating LD-adjusted regional scores. 
However, with inclusion of thousands of SNPs, the predictive capacity did not improve but showed a 
lower c-statistic in the range of 0.58 to 0.59, which is probably due to the cost of adding noise from 
SNPs that were not truly associated with CRC. To assess if the genetic susceptibility of known risk 
factors of CRC would further contribute to CRC prediction, we developed prediction models, which 
incorporated genetic information of several known risk factors, but the c-statistic remained close to 0.60.  
Most previous efforts mainly focused on the predictive ability of PRS to capture the overall risk of 
CRC.4, 5, 22-24 However, there is compelling evidence suggesting that genetic risk factors may differ by 
anatomic locations.25 We therefore aimed to improve prediction of site-specific CRC by deconstructing 
the commonly used genomic risk score into several regional scores, allowing susceptibility signals 
through multiple/different mechanisms to influence genetic predisposition to site-specific CRC. 
Although we treated proximal, distal and rectal cancer as distinct endpoints to generate the best set of 
regional scores respectively, their predictive performance still showed modest discriminative ability. 
This might be limited by the fact that the weights used for regional score calculation were derived from 
the coefficient estimates for overall CRC instead of site-specific ones. 
An extrapolation to the UK population led to the conclusion that 10% of the general population will 
have a 10-years absolute risk approaching 5% after 65 years old on the basis of quantifiable genetic risk 
alone and who will merit intensive screening. A 5% threshold of absolute risk has clinical and public 
health impact since it exceeds the highest risk at any age in the general population and it is 10-fold 
greater than the risk of a 50-year old person who is eligible to enter the population-based screening 
programs. Additionally, the modelling shows individuals at different levels of the wPRS116 will reach 
the same risk estimate at different ages, supporting the notion that using genetic profiling in combination 
with age will lead to more effective risk stratification.   
In conclusion, we show that prediction of CRC risk based on profiling with common genetic variants 
presents a moderate discriminability. Although the contribution of wPRS116 to individualized risk 
profiling is limited, employing genetic risk profiling can achieve a moderate degree of risk 
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